Inserm UMR_S 1116, Vandoeuvre-Lès-Nancy, France.
Université de Lorraine, Vandoeuvre-Lès-Nancy, France.
Oxid Med Cell Longev. 2020 Jan 14;2020:5197376. doi: 10.1155/2020/5197376. eCollection 2020.
Calcific aortic valve stenosis (CAVS) is a common disease associated with aging. Oxidative stress participates in the valve calcification process in CAVS. Semicarbazide-sensitive amine oxidase (SSAO), also referred to as vascular adhesion protein 1 (VAP-1), transforms primary amines into aldehydes, generating hydrogen peroxide and ammonia. SSAO is expressed in calcified aortic valves, but its role in valve calcification has remained largely unexplored. The aims of this study were to characterize the expression and the activity of SSAO during aortic valve calcification and to establish the effects of SSAO inhibition on human valvular interstitial cell (VIC) calcification.
Human aortic valves from = 80 patients were used for mRNA extraction and expression analysis, Western blot, SSAO activity determination, immunohistochemistry, and the isolation of primary VIC cultures.
SSAO mRNA, protein, and activity were increased with increasing calcification within human aortic valves and localized in the vicinity of the calcified zones. The valvular SSAO upregulation was consistent after stratification of the subjects according to cardiovascular and CAVS risk factors associated with increased oxidative stress: body mass index, diabetes, and smoking. SSAO mRNA levels were significantly associated with poly(ADP-ribose) polymerase 1 (PARP1) in calcified tissue. Calcification of VIC was inhibited in the presence of the specific SSAO inhibitor LJP1586.
The association of SSAO expression and activity with valvular calcification and oxidative stress as well as the decreased VIC calcification by SSAO inhibition points to SSAO as a possible marker and therapeutic target to be further explored in CAVS.
钙化性主动脉瓣狭窄(CAVS)是一种与衰老相关的常见疾病。氧化应激参与 CAVS 中的瓣膜钙化过程。氨基脲敏感胺氧化酶(SSAO),也称为血管黏附蛋白 1(VAP-1),将伯胺转化为醛,生成过氧化氢和氨。SSAO 在钙化的主动脉瓣中表达,但它在瓣膜钙化中的作用在很大程度上仍未得到探索。本研究旨在描述 SSAO 在主动脉瓣钙化过程中的表达和活性,并确定 SSAO 抑制对人瓣膜间质细胞(VIC)钙化的影响。
从 = 80 名患者中提取人主动脉瓣 mRNA 进行提取和表达分析、Western blot、SSAO 活性测定、免疫组织化学和原代 VIC 培养物分离。
SSAO mRNA、蛋白和活性随着人主动脉瓣内钙化的增加而增加,并定位于钙化区附近。根据与氧化应激增加相关的心血管和 CAVS 危险因素对受试者进行分层后,瓣膜 SSAO 的上调是一致的:体重指数、糖尿病和吸烟。SSAO mRNA 水平与钙化组织中的多聚(ADP-核糖)聚合酶 1(PARP1)显著相关。在特异性 SSAO 抑制剂 LJP1586 的存在下,VIC 的钙化被抑制。
SSAO 的表达和活性与瓣膜钙化和氧化应激相关,以及 SSAO 抑制对 VIC 钙化的减少表明 SSAO 可能是 CAVS 中进一步探索的标志物和治疗靶点。